A Phase 2 interventional study of STI571 400 mg and STI571 600 mg in Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 3 open to participants now, 4 under way, 2 of them phase 3. imatinib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 1999, is one of 16 in phase 2, and was the 12th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →3 of the 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Goethe University · Sites in Germany
Ages 18–65
Mats Heyman · Sites in Belgium, Denmark, Estonia and 12 more countries
Ages 0–45
National University Hospital, Singapore · Sites in Malaysia, Singapore
Ages up to 40
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 18 · Phase 3 4 · Phase 4 2
First in 1999; this study’s year is marked. 2 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 293 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 70 across the 27 interventional studies. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Novartis: 3 open now, 5 under way, 1 of them phase 3. Of 26 finished, 17 (65%) have results posted.
Among the 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Novartis, this one is the 4th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 1999, is one of 10 in phase 2, and was the 4th registered.
Novartis’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 34 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
This tab as a report to print or save as PDF → With an account.
The objectives of Part 1 of the study were:
The objective of the extension (Part 2) was:
-To enable participants to have access to study drug and continue study treatment and to decrease data collection to include only overall survival and serious adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female participants, aged ≥18 years, with a confirmed diagnosis of Ph+ leukemia of one of the following types:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
Drug: STI571 400 mg
Participants with lymphoid blast crisis received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
Drug: STI571 400 mg
Participants with acute lymphoblastic leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
Drug: STI571 400 mg
Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
Drug: STI571 600 mg
Participants with lymphoid blast crisis received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
Drug: STI571 600 mg
Participants with acute lymphoblastic leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
Drug: STI571 600 mg
Participants with acute myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
Drug: STI571 600 mg
STI571 capsules and tablets
Also known as: Imatinib mesylate, Glivec®, GleevecTM
STI571 capsules and tablets
Also known as: Imatinib mesylate, Glivec®, GleevecTM
Percentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
Hematologic response was evaluated from hematology measurements in the peripheral blood (PB) and bone marrow (BM) and assessments of extramedullary leukemic involvement (EMD) at physical examination. Response was defined as complete hematologic remission (CHR), no evidence of leukemia (NEL), or return to chronic phase (RTC).
Time frame: Up to 3 years after start of treatment
Percentage of Participants With Cytogenetic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
Bone marrow (BM) cytogenetic analysis was required at baseline, after 12 weeks (visit 22) and after 24 weeks (visit 28) to evaluate Ph chromosome positivity. In several participants, this was also done after 4 and 8 weeks. Based on the percentage of Philadelphia chromosome positive (Ph+) cells = (positive cells/examined cells)x100, at each BM assessment the cytogenetic response was classified as: Complete, 0% Ph+ cells; Partial, \>0 - 35% Ph+ cells; Minor, \>35 - 65% Ph+ cells; Minimal, \>65 - 95% Ph+ cells; None, \>95% Ph+ cells; Not done: \<20 metaphases were examined and/or response could not be assigned. Cytogenetic response was defined as confirmed complete or partial response. A BM sample was considered as assessable for cytogenetic response only if it contained ≥20 metaphases. However, an assessment of partial response was retained in a sample with \<20 metaphases when it was immediately preceded or followed by a complete or partial response in another sample with ≥20 metaphases.
Time frame: Up to 3 years after start of treatment
Time to Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
Time to response was defined for all participants as the time until first documented response (which was confirmed ≥4 weeks later).
Time frame: Up to 3 years after start of treatment
Duration of Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
Duration of response was defined as the time between first documented response (which was confirmed ≥4 weeks later) and the earliest date of the following: loss of response (when any of the criteria for response were no longer fulfilled); progression to blast crisis (≥30% blasts in peripheral blood or bone marrow, extramedullary involvement other than liver/spleen enlargement); discontinuation due to adverse event, laboratory abnormality, unsatisfactory therapeutic effect or death.
Time frame: Up to 3 years after start of treatment
Time to Progression to Blast Crisis in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
Progression to blast crisis was defined as ≥30% blasts in peripheral blood or bone marrow or as extramedullary involvement other than liver or spleen enlargement.
Time frame: Up to 3 years after start of treatment
Overall Survival by Disease
To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.
Time frame: 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156 months after start of treatment
Overall Survival by Dose in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.
Time frame: 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 months after start of treatment
Participants took part in this study at 14 investigative sites in France, Germany, Italy, United Kingdom, Switzerland and United States from August 9, 1999 to September 23, 2013.
| Milestone | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg | Lymphoid Blast Crisis 400 mg | Acute Lymphoblastic Leukemia 400 mg | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg | Lymphoid Blast Crisis 600 mg | Acute Lymphoblastic Leukemia 600 mg | Acute Myeloid/Myelogenous Leukemia 600 mg |
|---|---|---|---|---|---|---|---|
| Started | 77 | 5 | 5 | 158 | 3 | 43 | 2 |
| Completed part 1 | 50 | 0 | 1 | 125 | 2 | 6 | 0 |
| Completed | 1 | 0 | 0 | 6 | 0 | 0 | 0 |
| Not completed | 76 | 5 | 5 | 152 | 3 | 43 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 6 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 44 | 3 | 5 | 70 | 3 | 31 | 1 |
| Withdrew: Death | 7 | 1 | 0 | 4 | 0 | 3 | 1 |
| Withdrew: Other | 10 | 0 | 0 | 43 | 0 | 2 | 0 |
| Withdrew: No longer requires study drug | 4 | 0 | 0 | 3 | 0 | 5 | 0 |
| Withdrew: Administrative problems | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 0 | 15 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 5 | 0 | 0 | 9 | 0 | 0 | 0 |
Hematologic response was evaluated from hematology measurements in the peripheral blood (PB) and bone marrow (BM) and assessments of extramedullary leukemic involvement (EMD) at physical examination. Response was defined as complete hematologic remission (CHR), no evidence of leukemia (NEL), or return to chronic phase (RTC).
| percentage of participants | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg |
|---|---|---|
| Percentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia | 64.9 (53.2 to 75.5) | 74.7 (67.2 to 81.3) |
Bone marrow (BM) cytogenetic analysis was required at baseline, after 12 weeks (visit 22) and after 24 weeks (visit 28) to evaluate Ph chromosome positivity. In several participants, this was also done after 4 and 8 weeks. Based on the percentage of Philadelphia chromosome positive (Ph+) cells = (positive cells/examined cells)x100, at each BM assessment the cytogenetic response was classified as: Complete, 0% Ph+ cells; Partial, \>0 - 35% Ph+ cells; Minor, \>35 - 65% Ph+ cells; Minimal, \>65 - 95% Ph+ cells; None, \>95% Ph+ cells; Not done: \<20 metaphases were examined and/or response could not be assigned. Cytogenetic response was defined as confirmed complete or partial response. A BM sample was considered as assessable for cytogenetic response only if it contained ≥20 metaphases. However, an assessment of partial response was retained in a sample with \<20 metaphases when it was immediately preceded or followed by a complete or partial response in another sample with ≥20 metaphases.
| percentage of participants | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg |
|---|---|---|
| Percentage of Participants With Cytogenetic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia | 14.3 (7.4 to 24.1) | 24.7 (18.2 to 32.2) |
Time to response was defined for all participants as the time until first documented response (which was confirmed ≥4 weeks later).
| months | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg |
|---|---|---|
| Hematologic response | 0.95 (0.95 to 1.1) | 0.99 (0.99 to 1) |
| Cytogenetic response | 2.83 (1.9 to 5.6) | 2.96 (2.8 to 5.5) |
Duration of response was defined as the time between first documented response (which was confirmed ≥4 weeks later) and the earliest date of the following: loss of response (when any of the criteria for response were no longer fulfilled); progression to blast crisis (≥30% blasts in peripheral blood or bone marrow, extramedullary involvement other than liver/spleen enlargement); discontinuation due to adverse event, laboratory abnormality, unsatisfactory therapeutic effect or death.
| months | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg |
|---|---|---|
| Hematologic response | 16.46 (10.4 to 27.4) | 28.81 (25.7 to NA) |
| Cytogenetic response | 26.28 (6.6 to NA) | 27.63 (15.9 to NA) |
Progression to blast crisis was defined as ≥30% blasts in peripheral blood or bone marrow or as extramedullary involvement other than liver or spleen enlargement.
| months | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg |
|---|---|---|
| Time to Progression to Blast Crisis in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia | 9.95 (6.6 to 14.4) | 25.13 (18.1 to 29.8) |
To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.
| percentage of participants | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia | Lymphoid Blast Crisis | Acute Lymphoid Leukemia | Acute Myeloid/Myelogenous Leukemia |
|---|---|---|---|---|
| 12 months | 74.4 (68.3 to 79.5) | 12.5 (0.7 to 42.3) | 10.4 (3.8 to 20.9) | 0 (0 to 0) |
| 24 months | 58.8 (52.2 to 64.8) | 0 (0 to 0) | 8.3 (2.7 to 18.2) | 0 (0 to 0) |
| 36 months | 48 (41.4 to 54.2) | 0 (0 to 0) | 8.3 (2.7 to 18.2) | 0 (0 to 0) |
| 48 months | 39.9 (33.5 to 46.2) | 0 (0 to 0) | 8.3 (2.7 to 18.2) | 0 (0 to 0) |
| 60 months | 32.2 (26.1 to 38.4) | 0 (0 to 0) | 8.3 (2.7 to 18.2) | 0 (0 to 0) |
| 72 months | 26.3 (20.6 to 32.3) | 0 (0 to 0) | 8.3 (2.7 to 18.2) | 0 (0 to 0) |
| 84 months | 24.1 (18.6 to 30.1) | 0 (0 to 0) | 8.3 (2.7 to 18.2) | 0 (0 to 0) |
| 96 months | 21.9 (16.5 to 27.8) | 0 (0 to 0) | 5.6 (1.2 to 15.2) | 0 (0 to 0) |
| 108 months | 20.6 (15.3 to 26.4) | 0 (0 to 0) | 5.6 (1.2 to 15.2) | 0 (0 to 0) |
| 120 months | 20.6 (15.3 to 26.4) | 0 (0 to 0) | 5.6 (1.2 to 15.2) | 0 (0 to 0) |
| 132 months | 18.9 (13.6 to 24.8) | 0 (0 to 0) | 5.6 (1.2 to 15.2) | 0 (0 to 0) |
| 144 months | 18.9 (13.6 to 24.8) | 0 (0 to 0) | 5.6 (1.2 to 15.2) | 0 (0 to 0) |
| 156 months | 18.9 (13.6 to 24.8) | 0 (0 to 0) | 5.6 (1.2 to 15.2) | 0 (0 to 0) |
To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.
| percentage of participants | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg | Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg |
|---|---|---|
| 12 months | 64.5 (52.6 to 74.1) | 79.1 (71.9 to 84.7) |
| 24 months | 44.3 (32.9 to 55.1) | 65.7 (57.7 to 72.6) |
| 36 months | 34.9 (24.4 to 45.7) | 54.2 (46.0 to 61.6) |
| 48 months | 28.0 (18.4 to 38.5) | 45.6 (37.6 to 53.2) |
| 60 months | 23.7 (14.7 to 33.9) | 36.2 (28.6 to 43.9) |
| 72 months | 18.6 (10.5 to 28.5) | 29.9 (22.6 to 37.5) |
| 84 months | 15.2 (7.8 to 24.8) | 28.3 (21.2 to 35.9) |
| 96 months | 11.8 (5.4 to 21.0) | 26.6 (19.6 to 34.2) |
| 108 months | 11.8 (5.4 to 21.0) | 24.8 (17.9 to 32.3) |
| 120 months | 11.8 (5.4 to 21.0) | 24.8 (17.9 to 32.3) |
| 132 months | 11.8 (5.4 to 21.0) | 22.3 (15.4 to 29.9) |
Collected over Up to approximately 14 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| STI571 | — | 20/293 (6.8%) | — |
| Event | STI571 |
|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/293 |
| DeathGeneral disorders | 2/293 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/293 |
| Transfusion reactionInjury, poisoning and procedural complications | 1/293 |
| Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/293 |
| Gastrointestinal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/293 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/293 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 1/293 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/293 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/293 |
Intention-to-treat (ITT) population consisted of all enrolled participants. Baseline characteristics were collected and reported together for each disease and dose groups (Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg or 600 mg, Lymphoid Blast Crisis 400 mg or 600 mg, Acute Lymphoblastic Leukemia 400 mg or 600 mg, and Acute Myeloid/Myelogenous Leukemia 600 mg) of participants, as pre-specified in the protocol.
| Age, Continuous(years) | STI571 |
|---|---|
| Mean | 54.3 ± 12.84 |
| Sex: Female, Male(Participants) | STI571 |
|---|---|
| Female | 146 |
| Male | 147 |
Ran from Aug 1999 to primary completion in Sep 2013, 169 months.
Results were first posted in Jul 2021, 7 years 9 months after primary completion.
Of 227 phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's 169 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Precursor Cell Lymphoblastic Leukemia-Lymphoma →